瑞格列奈与氯吡格雷合用增加低血糖风险:基于人群的巢式病例对照研究
该巢式病例对照研究评估瑞格列奈与氯吡格雷的潜在相互作用,以因低血糖住院或急诊就诊为病例,暴露为低血糖事件前3天内两药合用,按年龄、性别、格列奈类型及入组时间匹配对照。结果显示合用较单用瑞格列奈低血糖风险升高(校正OR 2.42;95%CI 1.75-3.35),而阴性对照组合用未见显著关联。
要点
- 瑞格列奈与氯吡格雷合用较低血糖风险显著升高(校正OR 2.42)。
- 阴性对照(那格列奈+氯吡格雷、瑞格列奈+阿司匹林)未见显著关联。
- 临床应关注两药合用患者的低血糖风险。
核心结论
- 瑞格列奈与氯吡格雷合用与低血糖风险升高相关,提示该药物相互作用具有临床意义。
研究设计与样本
- 巢式病例对照研究,病例定义为因低血糖住院或急诊就诊,暴露为事件前3天内合用瑞格列奈与氯吡格雷。
- 每个病例按年龄、性别、格列奈类型及入组时间匹配最多4名对照,采用条件logistic回归估计风险。
主要发现
- 瑞格列奈与氯吡格雷合用较单用瑞格列奈的低血糖风险升高(校正OR 2.42;95%CI 1.75-3.35)。
- 那格列奈与氯吡格雷合用、瑞格列奈与阿司匹林(未用氯吡格雷)合用均未见显著关联。
关键数值与推荐
- 合用瑞格列奈与氯吡格雷的低血糖校正OR为2.42(95%CI 1.75-3.35)。
临床怎么用
- 临床对合用瑞格列奈与氯吡格雷的患者应加强低血糖监测与风险教育。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This nested case-control study evaluated the potential interaction between repaglinide and clopidogrel. Cases were defined by inpatient admissions or emergency department visits due to hypoglycemia. Concomitant use of repaglinide and clopidogrel within 3 days before the hypoglycemic event was the exposure of interest. For each case, up to four controls were randomly selected and matched by age, sex, type of glinide used (repaglinide or nateglinide), and time since cohort entry to the index date. Hypoglycemic risk was estimated by conditional logistic regressions. Concomitant use of repaglinide and clopidogrel was associated with an increased risk of hypoglycemia compared with repaglinide alone (adjusted odds ratio: 2.42; 95% confidence interval: 1.75-3.35). No significant associations were found with the two negative control object drug concomitants: nateglinide and clopidogrel and repaglinide and aspirin (without clopidogrel use). Our study suggests drug interaction between clopidogrel and repaglinide is clinically relevant and could increase the risk for hypoglycemia.
引用
- Wei Y, Lin FJ, Lin SY, et al. Risk of Hypoglycemia and Concomitant Use of Repaglinide and Clopidogrel: A Population-Based Nested Case-Control Study. Clin Pharmacol Ther. 2019. PMID: 31216051. doi:10.1002/cpt.1556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。